



PCT/1804/3726



INVESTOR IN PEOPLE

BEST AVAILABLE COPY

REC'D 0 2 FEB 2005	
WIPO	PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

William Morell

Dated 27 January 2005

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Patents Form 1/77


Patents Act 1977
(Rule 16)



22MAR04 E882590-1 D00060
FOI/7700 0.00-0406296.4 NONE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

NRS/FP6206650

2. Patent application number

0406296.4

(The Patent Office will fill this part in)

19 MAR 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)

SWETREE TECHNOLOGIES AB
PO BOX 7981
SE-90719
UMEA
SWEDEN

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

8704660001
SE

4. Title of the invention

POLYPEPTIDE EXPRESSION IN PLANTS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP

Patents ADP number (if you know it)

109006

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

YES

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	0
Description	41
Claim(s)	6
Abstract	0
Drawing(s)	3

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for a preliminary examination and search (Patents Form 9/77)	0
Request for a substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	0

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

N Sutcliffe

Date 18 March 2004

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

NICHOLAS R BUTCLIFFE

020 7240 4405

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part-8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Polypeptide Expression in Plants

This invention relates to methods and means for the
5 expression of plastid-targeted polypeptides in plants.

Plastids are membrane-bound organelles within plant cells
which have a variety of cellular functions. Examples of
plastids include chloroplasts, proplastids, chromoplasts,
10 etioplasts and leucoplasts, such as amyloplasts and
proteinoplasts.

Although some plastid proteins are encoded by plastid DNA
and synthesised within the plastid, most plastid proteins
are encoded by the nuclear genome and synthesized in the
15 cytosol as precursors. These precursors contain an amino-
terminal transit peptide that is both necessary and
sufficient to direct the transport of the precursor from
the cytosol, across the outer and inner envelope
membranes, into the plastid stroma, where the transit
20 peptide is cleaved off to generate the mature protein
(Keegstra, K. & Cline, K. *Plant Cell* 11 557-570 (1999)).
In the chloroplast, for example, a hetero-oligomeric
molecular machine known as the Tic/Toc translocon complex
(Soll, J. *Curr. Opin Plant Biol.* 5, 529-535 (2002)), which
25 is located in the chloroplast envelope membranes,
mediates the specific recognition and translocation of
precursor proteins into the chloroplast.

The present inventors have recognised that certain
30 plastid-localised proteins in plants are not, in fact,
targeted directly to the plastid from the cytosol but are
instead directed to the endoplasmic reticulum and become
glycosylated before entering the plastid stroma. This

finding has significant utility in the expression of recombinant polypeptides in plants.

One aspect of the invention provides a method of
 5 producing a recombinant polypeptide comprising;
 expressing in a plant cell a nucleic acid encoding a fusion polypeptide which comprises said recombinant polypeptide, an ER signal sequence and one or more ER-plastid targeting sequences.

10

The expressed fusion polypeptide may subsequently be cleaved to produce said recombinant polypeptide.

The ER signal sequence and one or more ER-plastid
 15 targeting sequences are preferably heterologous to the recombinant polypeptide. The ER signal sequence and one or more ER-plastid targeting sequences may be from the same or different sources.

20 The ER signal sequence directs the localisation of the polypeptide from the cytosol to the ER. A suitable ER signal sequence may comprise at least 20, at least 22 or more preferably at least 24 amino acids. The ER signal sequence is preferably a plant ER signal sequence, for
 25 example a plant ER signal sequence from the N terminal of an ER-processed plastid polypeptide. Examples of ER-processed plastid polypeptides from chloroplasts are shown in Table 1.

30 Examples of suitable ER signal-sequence include;
 MKIMMMIKLCFFSMSLICAPADA,
 MAASHGNAIFVLLLCTFLPSLAC, and;
 MAARIGIFSVFVAVLLSISAFSSA.

Other examples of ER signal sequences are described in Emanuelsson et al *J. Mol. Biol.* 300, 1005-1016 (2000).

ER-plastid targeting sequences direct the transit of
5 polypeptides within the plant cell from the microsomes
(i.e. the ER or Golgi) to a plastid, which may, for
example, be a proplastid, chromoplast, etioplast,
leucoplastid (e.g. amyloplast or proteinoplast) or
chloroplast. In some preferred embodiments, the ER-
10 plastid targeting sequence is an ER-chloroplast targeting
sequence which directs the transit of a polypeptide to
the chloroplast.

A suitable ER-plastid targeting sequence may comprise a
15 sequence of at least 10 contiguous amino acids, more
preferably 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120
or more contiguous amino acids from an ER-processed
plastid polypeptide or an allele, variant or derivative
thereof, in particular from the N or C terminal of an ER-
20 processed plastid polypeptide or an allele, variant or
derivative thereof. A targeting sequence from an ER-
processed polypeptide from a particular plastid may be
used to target polypeptide to that plastid. In some
preferred embodiments, the full-length sequence of an ER-
25 processed plastid polypeptide or an allele, variant or
derivative thereof may be employed i.e. the one or more
ER-plastid targeting sequences are comprised within an ER-
processed plastid polypeptide. Examples of ER-processed
plastid polypeptides found in the chloroplast are shown
30 in Table 1. ER-processed plastid polypeptides from other
plastids, for example proplastids, chromoplasts,
etioplasts, or leucoplastids, may be readily identified
using standard techniques, as described herein.

One, two, three or more ER-plastid targeting sequences may be employed within a fusion polypeptide as described herein.

- 5 In some embodiments, an ER-plastid targeting sequence may comprise or consist of a 12 to 15 amino acid sequence from the C terminal of an ER-processed plastid polypeptide. Such a sequence may be hydrophilic and, in some preferred embodiments, may comprise 2, 3, 4 or more
 10 contiguous basic residues, in particular lysine and/or arginine residues. For example, a ER-plastid targeting sequence may be comprise or consist of the amino acid sequence KKETGNKKKKPN, RFWGKKKRRSSP or TGKKKKKTYLP. Other suitable sequences may be obtained from the C terminal
 15 region (i.e. the C terminal 20-30 amino acids) of a sequence shown in Table 1.

- In some embodiments, the one or more ER-plastid targeting sequence may comprise or consist of residues 25 to 114
 20 and/or residues 224 to 285 of a CAH1 polypeptide, for example *A. thaliana* CAH1. In some preferred embodiments, the fusion protein may further comprise an ER signal sequence comprising or consisting of residues 1 to 24 of CAH1 as described above. Thus, a fusion polypeptide may
 25 comprise, in an N to C direction, residues 1 to 114 of CAH1, a sequence encoding a recombinant polypeptide, and residues 224 to 285 of CAH1. In some particularly preferred embodiments, the fusion polypeptide may comprise the full-length CAH1 sequence.
- 30 The recombinant polypeptide may be upstream (i.e. towards the N terminal) or downstream (i.e. towards the C terminal) of the one or more ER-plastid targeting sequences within the fusion polypeptide, or may be

located between two or more ER-plastid targeting sequences.

For example, in some embodiments, a recombinant polypeptide may be joined directly or indirectly to the N terminal or C terminal of an ER-processed plastid polypeptide within the fusion polypeptide, or may be located within the ER-processed plastid polypeptide sequence (i.e. surrounded by sequence from the ER-processed plastid polypeptide).

Recombinant polypeptide may be generated from the fusion polypeptide by any convenient means. Typically, proteolytic cleavage of the fusion polypeptide using one or more endoproteases may be employed. Suitable endoproteases may include site-specific endoproteases, such as rennin, factor Xa and thrombin, or other endoproteases known in the art.

In some embodiments, an endoprotease may be present within the plastid, either as an endogenous plant polypeptide, such as SPP, (Richter et al J. Biol. Chem. (2002) 277: 43888-43894), DEG (Itzhaki et al J. Biol. Chem. (1998) 273: 7094-7098) or FTSH, or as a recombinant polypeptide expressed from a heterologous nucleic acid. The expressed fusion polypeptide may thus undergo *in situ* proteolysis to produce the recombinant polypeptide within the plastid.

To facilitate cleavage by endoproteases, the recombinant polypeptide sequence may be linked to heterologous sequences within the fusion polypeptide, such as the ER signal sequence and ER-plastid targeting sequences, by cleavable linkers. Suitable linker sequences are well

known in the art and may include, for example, substrate sequences for thrombin, rennin, and factor X. Other suitable linker sequences are described in Richter et al J. Biol. Chem. (2002) 277: 43888-43894.

5

After cleavage of the fusion polypeptide to produce the recombinant polypeptide, the recombinant polypeptide may be isolated and/or purified from the plastid. Plastids may be isolated from the plant cell in a preliminary

10 purification, prior to purification of the recombinant polypeptide from the isolated plastids. Alternatively, recombinant polypeptide may be isolated directly from the plant cells.

15 In other embodiments, the fusion polypeptide may be isolated and/or purified from the plastid prior to the generation of the recombinant polypeptide. For example, the fusion polypeptide may be isolated and treated with endoproteases to liberate the recombinant polypeptide.

20

Expressed polypeptide may be extracted, isolated and/or purified from plants or plant material by any convenient method. For example, the plant material may be homogenised, solvent extracted and subjected to

25 chromatographic separation methods such as HPLC and column chromatography, for example using a silica column. In some embodiments, the expressed polypeptide is glycosylated and glycosylation-specific purification methods may be employed, for example using a column

30 containing immobilised lectin or glycosyl-specific antibodies.

In some preferred embodiments, a recombinant polypeptide may be produced in accordance with the invention by

expressing in a plant cell a nucleic acid encoding a fusion polypeptide which comprises said recombinant polypeptide linked to an ER-processed plastid polypeptide.

5

The recombinant polypeptide may subsequently be cleaved from the ER-processed plastid polypeptide.

10

The recombinant polypeptide or the fusion polypeptide may be isolated and/or purified from the plastid following said expression.

15

As described above, the ER processed plastid polypeptide may be positioned downstream (i.e. towards the C terminal) or more preferably upstream (i.e. towards the N terminal) of the recombinant polypeptide, or may be located within the ER-processed plastid polypeptide sequence (i.e. surrounded by sequence from the ER-processed plastid polypeptide).

20

Preferably, the fusion polypeptide comprises an N terminal ER signal sequence. In embodiments in which the ER-processed plastid polypeptide is upstream of the recombinant polypeptide, the ER signal sequence may be comprised within the ER-processed plastid polypeptide sequence.

30

An ER processed plastid polypeptide is a polypeptide located in the plastid which is post-translationally targeted to the plastid via the ER. Suitable ER processed plastid polypeptides may be identified by standard *in silico* analysis and data mining techniques. For example, ER processed chloroplast polypeptides may be identified from sequences obtained by chloroplast

proteome initiatives (Friso, G et al (2004) Plant Cell (in press), T. Kleffmann, et al (2004) Current Biology (in press)). ER processed chloroplast polypeptides from these databases, which contain an ER signal peptide but
 5 lack a C-terminal H/KDEL ER-retention signal, are shown in Table 1. Gene ID's are based on the Arabidopsis Genome Initiative (Nature (2000) 408(6814):796-815).

ER processed plastid polypeptides may comprise an N-
 10 terminal ER signal sequence as identified by targetP predictions. They may further comprise a hydrophilic C- or N-terminal, for example comprising 2 or more basic residues, in particular lysines and/or arginine residues.

15 In some embodiments, an ER processed plastid polypeptide may comprise one or more glycosylation sites, preferably N-glycosylation sites. These sites may be glycosylated when the polypeptide is expressed in plant cells.

Suitable ER processed plastid polypeptides include
 20 Arabidopsis CAH1 (U73462), Rice CAH1 (CAD40654), Arabidopsis ribophorin 1 and other sequences which are set out in Table 1.

Whilst a wild-type ER processed plastid polypeptide is
 25 preferred in the fusion polypeptides described herein, an ER processed plastid polypeptide which is a fragment, mutant, derivative, variant or allele of such a wild type sequence may also be used

30 Suitable fragments, mutants, derivatives, variants and alleles of ER processed plastid polypeptides retain the signals required for targeting to the plastid via the ER. A mutant, variant or derivative may have one or more of

addition, insertion, deletion or substitution of one or more amino acids in the polypeptide sequence. Such alterations may be caused by one or more of addition, insertion, deletion or substitution of one or more
5 nucleotides in the encoding nucleic acid.

A polypeptide which is an amino acid sequence variant, allele, derivative or mutant of an ER processed plastid polypeptide such as CAH1, for example Arabidopsis CAH1
10 (U73462) or a sequence shown in Table 1, may comprise an amino acid sequence which shares greater than about 30% sequence identity with the wild-type polypeptide sequence, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 55%, greater
15 than about 65%, greater than about 70%, greater than about 80%, greater than about 90% or greater than about 95%. The sequence may share greater than about 30% similarity with the wild-type ER processed plastid polypeptide sequence, greater than about 40% similarity,
20 greater than about 50% similarity, greater than about 60% similarity, greater than about 70% similarity, greater than about 80% similarity or greater than about 90% similarity.

25 Sequence similarity and identity are commonly defined with reference to the algorithm GAP (Genetics Computer Group, Madison, WI). GAP uses the Needleman and Wunsch algorithm to align two complete sequences that maximizes the number of matches and minimizes the number of gaps.
30 Generally, default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4. Use of GAP may be preferred but other algorithms may be used, e.g.. BLAST (which uses the method of Altschul et al. (1990) *J. Mol. Biol.* 215: 405-410), FASTA (which uses

the method of Pearson and Lipman (1988) *PNAS USA* 85: 2444-2448), or the Smith-Waterman algorithm (Smith and Waterman (1981) *J. Mol Biol.* 147: 195-197), or the TBLASTN program, of Altschul et al. (1990) *supra*,

5 generally employing default parameters. In particular, the psi-Blast algorithm (Nucl. Acids Res. (1997) 25 3389-3402) may be used. Sequence identity and similarity may also be determined using GenomequestTM software (Gene-IT, Worcester MA USA).

10

Sequence comparisons are preferably made over the full-length of the relevant sequence described herein.

Similarity allows for "conservative variation", i.e.

15 substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine.

20

The recombinant polypeptide which is expressed using the methods described herein may be any polypeptide of interest. The present methods are particularly suitable for the expression of glycosylated polypeptides. Suitable
25 polypeptides may include vaccines (for example, vaccines against hepatitis B virus envelope protein, human cytomegalovirus glycoprotein B or Norwalk virus capsid protein), antibodies or antibody fragments, pharmaceutical proteins such as signal peptides, protein
30 hormones, structural proteins such as collagen, blood proteins such as serum albumin, enzymes such as secreted alkaline phosphatase, industrial enzymes and enzymes that produce a secondary or new metabolite/chemical compound in the plastid. Other examples of recombinant

polypeptides are described in Trends in Plant Science (2001) 6 5 219-226 and Ma et al Nature Reviews Genetics 4, 794 -805 (2003).

- 5 In some preferred embodiments, the recombinant polypeptide may comprise one or more N-glycosylation sites (for example Asn-x-Thr/Ser sites) and/or O-glycosylation sites. Targeting to the plastid via the microsomes allows the glycosylation of such sites.
- 10 Methods as described herein are therefore especially suitable for the production of glycosylated recombinant polypeptides. The presence or amount of Glycosylation, for example by a xylose- or fucose-containing glycan, may be determined following production of the recombinant
- 15 polypeptide in the plant. Glycosylation may be determined by any convenient method. For example, the polypeptide may be contacted with an antibody specific for a glycosyl epitope, such as $\beta(1,2)$ -xylose or $\alpha(1,3)$ -fucose.
- 20 Methods of the invention allow the recombinant polypeptide to pass through the ER and the Golgi system, enabling N- and O- glycosylation and maturation of the glycosylation pattern. The glycosylation pattern may be a
- 25 plant glycosylation pattern, for example comprising $\beta(1,2)$ -xylose and/or $\alpha(1,3)$ -fucose residues. This is exemplified herein by the presence, in the glycosylated CAH1 protein described below, of fucose, which is added in the Golgi. In other embodiments, the glycosylation
- 30 pattern may be a mammalian glycosylation pattern, for example comprising $\alpha(1,6)$ -fucose residues.

A recombinant polypeptide expressed as described herein may thus comprise N- and/or O linked glycosyl residues.

Another aspect of the invention provides a nucleic acid construct comprising a nucleotide sequence which encodes an ER signal sequence and one or more ER-plastid

5 targeting sequences, the nucleotide sequence further comprising one or more restriction endonuclease sites (i.e. a cloning site), which are preferably suitable for insertion of a nucleotide coding sequence capable of expressing a recombinant (i.e. a heterologous)
10 polypeptide fused to said ER signal and plastid targeting sequences.

ER signal sequences and plastid targeting sequences are described above.

15

The nucleic acid construct may further comprise a nucleotide coding sequence encoding a recombinant polypeptide for expression as part of said fusion polypeptide, said coding sequence being inserted in the
20 cloning site. The invention encompasses an isolated nucleic acid comprising a nucleotide sequence which encodes a fusion protein in which a recombinant polypeptide is fused to an ER signal sequence and one or more ER-plastid targeting sequences.

25

In some embodiments, the nucleotide sequence encoding the ER-plastid targeting sequences, and preferably also the ER signal sequence, may be comprised within a nucleotide sequence encoding an ER processed plastid polypeptide.

30 According to such embodiments, a nucleic acid construct may comprise a nucleotide sequence which encodes an ER processed plastid polypeptide and one or more restriction endonuclease sites for insertion of a nucleotide coding

sequence capable of expressing a recombinant polypeptide fused to said ER processed plastid polypeptide.

Suitable ER processed plastid polypeptides are described
5 in more detail above.

The nucleic acid construct may further comprise a nucleotide sequence encoding one or more cleavable linkers which allow the liberation of the recombinant
10 polypeptide from the fusion polypeptide after expression. For example, the recombinant polypeptide may be fused to the ER signal sequence and ER-plastid targeting sequences by a cleavable linker. Suitable linkers may be cleaved by
15 a site-specific endoprotease such as thrombin, factor Xa or rennin.

The nucleotide sequence encoding the fusion polypeptide may be operably linked to a heterologous regulatory
20 sequence.

The regulatory sequence or element may be plant specific i.e. it may preferentially direct the expression (i.e. transcription) of a nucleic acid within a plant cell relative to other cell types. For example, expression
25 from such a sequence may be reduced or abolished in non-plant cells, such as bacterial or mammalian cells.

The heterologous regulatory sequence may be activated by a heterologous transcription factor, such as GAL4 or T7
30 polymerase. Nucleic acid encoding the heterologous transcription factor may be operably linked to a plant-specific promoter as described above so that expression of the heterologous transcription factor is plant specific and plant specific expression of the fusion

polypeptide by activation of the heterologous regulatory sequence. For example, a GAL4 transcription factor may be expressed using a CaMV35S promoter and may drive expression of a fusion polypeptide coding sequence which is operably linked to the GAL4 promoter. In other embodiments, T7 polymerase may be expressed using a CaMV35S promoter and may drive expression of a coding sequence which is operably linked to a T7 promoter.

10 The terms "heterologous" and "recombinant" are used to indicate that the sequence of nucleotides in question has been introduced into a nucleic acid construct or a plant cell or an ancestor thereof, using genetic engineering or recombinant means, i.e. by human intervention and is not naturally found in such a construct or cell. A sequence which is heterologous (i.e. exogenous or foreign) to another nucleotide sequence or host cell is not associated with that sequence or cell in nature.

20 A heterologous plant specific regulatory sequence may be an inducible promoter. Such a promoter may induce expression in response to a stimulus. This allows control of expression, for example, to allow optimal plant growth before fusion polypeptide production is induced.

25

The term "inducible" as applied to a promoter is well understood by those skilled in the art. In essence, expression under the control of an inducible promoter is "switched on" or increased in response to an applied

30 stimulus (which may be generated within a cell or provided exogenously). The nature of the stimulus varies between promoters. Whatever the level of expression is in the absence of the stimulus, expression from any inducible promoter is increased in the presence of the

correct stimulus. The preferable situation is where the level of expression increases in the presence of the relevant stimulus by an amount effective to cause production of polypeptide. Thus an inducible (or

- 5 "switchable") promoter may be used which causes a basic level of expression in the absence of the stimulus which causes little or no accumulation of polypeptide. Upon application of the stimulus, which may for example, be an increase in environmental stress, expression of
- 10 polypeptide is increased (or switched on).

Many examples of inducible promoters will be known to those skilled in the art.

- 15 Other suitable promoters may include the Cauliflower Mosaic Virus 35S (CaMV 35S) gene promoter that is expressed at a high level in virtually all plant tissues (Benfey et al, (1990) EMBO J 9: 1677-1684); the cauliflower meri 5 promoter that is expressed in the
- 20 vegetative apical meristem as well as several well localised positions in the plant body, e.g. inner phloem, flower primordia, branching points in root and shoot (Medford, J.I. (1992) *Plant Cell* 4, 1029-1039; Medford et al, (1991) *Plant Cell* 3, 359-370) and the *Arabidopsis*
- 25 *thaliana* LEAFY promoter that is expressed very early in flower development (Weigel et al, (1992) *Cell* 69, 843-859). Other suitable promoters may be tissue specific, for example seed or leaf specific, and/or specifically expressed at different times or developmental stages, for
- 30 example diurnally active promoters such as the CAH1 promoter.

The construct may further comprise a 5' un-translated region to control translational initiation efficiency and transcript stability and thereby enhance expression.

- 5 Nucleic acid sequences and constructs as described above may be comprised within a vector. Those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression, for example in a microbial or plant cell. Suitable vectors can be
- 10 chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. A vector may comprise a selectable marker to facilitate selection
- 15 of the transgenes under an appropriate promoter. For further details see, for example, *Molecular Cloning: a Laboratory Manual*: 3rd edition, Sambrook & Russell, 2001, Cold Spring Harbor Laboratory Press.
- 20 Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Protocols in Molecular*
- 25 *Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. Specific procedures and vectors previously used with wide success upon plants are described by Bevan, *Nucl. Acids Res.* (1984) 12, 8711-8721), and Guerineau and Mullineaux, (1993) *Plant*
- 30 *transformation and expression vectors*. In: *Plant Molecular Biology Labfax* (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148.

A method of producing a recombinant polypeptide as described herein may comprise incorporating a nucleic acid encoding a fusion polypeptide which comprises said recombinant polypeptide, an ER signal sequence and one or
5 more ER-plastid targeting sequences and;
expressing said nucleic acid to produce a recombinant polypeptide in a plastid of said cell

When incorporating or introducing a chosen gene construct
10 into a cell, certain considerations must be taken into account, well known to those skilled in the art. The nucleic acid to be inserted should be assembled within a construct or vector which contains effective regulatory elements which will drive transcription. There must be
15 available a method of transporting the constructor vector into the cell. Once the construct is within the cell, integration into the endogenous chromosomal material either will or will not occur. Finally, as far as plants are concerned, the target cell type must be such that
20 cells can be regenerated into whole plants.

Techniques well known to those skilled in the art may be used to introduce nucleic acid constructs and vectors into plant cells to produce transgenic plants which
25 comprise the heterologous fusion polypeptide coding sequence.

Agrobacterium transformation is one method widely used by those skilled in the art to transform dicotyledonous
30 species. Production of stable, fertile transgenic plants in almost all economically relevant monocot plants is also now routine: (Toriyama, et al. (1988) *Bio/Technology* 6, 1072-1074; Zhang, et al. (1988) *Plant Cell Rep.* 7, 379-384; Zhang, et al. (1988) *Theor Appl Genet* 76, 835-

- 840; Shimamoto, et al. (1989) *Nature* 338, 274-276; Datta, et al. (1990) *Bio/Technology* 8, 736-740; Christou, et al. (1991) *Bio/Technology* 9, 957-962; Peng, et al. (1991) International Rice Research Institute, Manila,
- 5 Philippines 563-574; Cao, et al. (1992) *Plant Cell Rep.* 11, 585-591; Li, et al. (1993) *Plant Cell Rep.* 12, 250-255; Rathore, et al. (1993) *Plant Molecular Biology* 21, 871-884; Fromm, et al. (1990) *Bio/Technology* 8, 833-839; Gordon-Kamm, et al. (1990) *Plant Cell* 2, 603-618;
- 10 D'Halluin, et al. (1992) *Plant Cell* 4, 1495-1505; Walters, et al. (1992) *Plant Molecular Biology* 18, 189-200; Koziel, et al. (1993) *Biotechnology* 11, 194-200; Vasil, I. K. (1994) *Plant Molecular Biology* 25, 925-937; Weeks, et al. (1993) *Plant Physiology* 102, 1077-1084;
- 15 Somers, et al. (1992) *Bio/Technology* 10, 1589-1594; WO92/14828). In particular, *Agrobacterium* mediated transformation is now a highly efficient alternative transformation method in monocots (Hiei et al. (1994) *The Plant Journal* 6, 271-282).
- 20
- The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) *Current Opinion in Biotechnology* 5, 158-162.; Vasil, et al. (1992)
- 25 *Bio/Technology* 10, 667-674; Vain et al., 1995, *Biotechnology Advances* 13 (4): 653-671; Vasil, 1996, *Nature Biotechnology* 14 page 702). Wan and Lemaux (1994) *Plant Physiol.* 104: 37-48 describe techniques for generation of large numbers of independently transformed
- 30 fertile barley plants.

Other methods, such as microprojectile or particle bombardment (US 5100792, EP-A-444882, EP-A-434616), electroporation (EP 290395, WO 8706614), microinjection

(WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) *Plant Tissue and Cell Culture*, Academic Press) direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome mediated DNA uptake (e.g. Freeman et al. *Plant Cell Physiol.* 29: 1353 (1984)), or the vortexing method (e.g. Kindle, *PNAS U.S.A.* 87: 1228 (1990d)) may be preferred where *Agrobacterium* transformation is inefficient or ineffective.

- 10 Physical methods for the transformation of plant cells are reviewed in Oard, 1991, *Biotech. Adv.* 9: 1-11.

Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, e.g. bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

- 20 Following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be entirely regenerated from cells, tissues and organs of the plant. Available techniques are reviewed in Vasil et al., *Cell Culture and Somatic Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications*, Academic Press, 1984, and Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989.

30

The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular

methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention, nor is the choice of technique for plant regeneration.

A method of making a plant cell as described herein may include introduction of a nucleic acid or a vector as described herein into a plant cell and causing or allowing recombination between the nucleic acid or vector and the plant cell genome to introduce the nucleic acid sequence into the plant cell genome.

The invention encompasses a plant cell which is transformed with a nucleic acid construct or vector as set forth above, i.e. containing a nucleic acid or vector as described above.

Within the cell, the heterologous nucleotide sequence(s) may be incorporated within the chromosome or may be extra-chromosomal. There may be more than one heterologous nucleotide sequence per haploid genome. This, for example, enables increased expression of the gene product compared with endogenous levels, as discussed below. A nucleic acid sequence comprised within a plant cell may be placed under the control of an externally inducible gene promoter, either to place expression under the control of the user or to achieve expression in response to a particular stimulus.

A plant cell may further comprise a heterologous nucleic acid sequence encoding a site-specific endoprotease, as described above. The heterologous nucleic acid sequence

comprises a sequence encoding a plastid transit peptide which directs the protease to the plastid. The expressed endoprotease may be used to cleave the fusion polypeptide to liberate the recombinant polypeptide *in situ* in the plastid.

A nucleic acid which is stably incorporated into the genome of a plant is passed from generation to generation to descendants of the plant, cells of which descendants may express the encoded fusion polypeptide.

A plant cell may contain a nucleic acid sequence encoding a fusion polypeptide as described herein as a result of the introduction of the nucleic acid sequence into an ancestor cell.

In preferred embodiments, the plant cell possesses glycosylation activity which adds one or more glycan groups to the fusion polypeptide prior to localisation in the plastid.

A glycan group may be N-linked to asparagine or O-linked to serine, threonine or hydroxyproline. In preferred embodiments, the glycan is N-linked to an asparagine residue of the fusion polypeptide.

In some embodiments, the plant may possess endogenous plant glycosylation activity which adds plant specific glycans to the fusion polypeptide. Plant glycosylation involves the modification of the core $\text{Man}_3\text{GlcNAc}_2$ glycan by $\alpha 1,3$ -fucosylation and $\beta 1,2$ -xylosylation to produce a mature plant glycan which comprises $\alpha 1,3$ fucose and $\beta 1,2$ xylose residues (Zeng et al (1997) J. Biol. Chem. 272 31340-31347).

In other embodiments, the plant may possess modified glycosylation activity which adds, for example, mammalian specific (e.g. human specific) glycans to the fusion polypeptide. Mammalian glycosylation produces a mammalian glycan which, for example, comprises α 1,6 fucose and does not contain xylose.

Glycosylation activity may be modified in a plant cell, for example by inhibiting endogenous plant glycosyl-transferases, such as fucosyl transferase or xylosyl transferase (Leiter H et al *J Biol Chem* (1999) 274:21830-21839) and/or expressing mammalian glycosyl-transferases, such as human 1,4 galactosyl-transferase (Lerouge, P. et al. 2000. *Curr. Pharmacol. Biotechnol.*, 1, 347-354; Bakker, H. et al. 2001 *Proc. Natl. Acad. Sci. U.S.A.*, 98, 2899-2904).

Methods for inhibiting gene expression and/or expressing heterologous genes in plant cells are well known in the art.

Methods described herein may further include sexually or asexually propagating or growing off-spring or a descendant of the plant regenerated from said plant cell.

A plant cell as described herein may be comprised in a plant, a plant part or a plant propagule, or an extract or derivative of a plant as described below.

Plants which include a plant cell as described herein are also provided, along with any part or propagule thereof, seed, selfed or hybrid progeny and descendants.

A plant cell may be a green algae cell, for example a *Chlamydomonas* spp (e.g. *Chlamydomonas reinhardtii*) or a *Chlorella* spp cell, or the plant cell may be a cell from a higher plant, for example a gymnosperm or an angiosperm. Suitable angiosperms include monocotyledons and dicotyledons.

Examples of suitable plants include tobacco, cucurbits, carrot, vegetable brassica, melons, capsicums, grape vines, lettuce, strawberry, oilseed brassica, sugar beet, Yam, wheat, barley, maize, rice, soyabeans, peas, sorghum, sunflower, tomato, potato, pepper, spinach, zinnia, chrysanthemum, carnation, poplar, eucalyptus, pine, firs and spruces.

In some preferred embodiments, cells of green algae such as *Chlamydomonas* or cells from dicotyledonous plants such as *Arabidopsis*, tobacco or poplar may be employed.

In addition to a plant, the present invention provides any clone of such a plant, seed, selfed or hybrid progeny and descendants, and any part or propagule of any of these, such as cuttings and seed, which may be used in reproduction or propagation, sexual or asexual. Also encompassed by the invention is a plant which is a sexually or asexually propagated off-spring, clone or descendant of such a plant, or any part or propagule of said plant, off-spring, clone or descendant.

A method of producing a plant may comprise incorporating nucleic acid as described above into a plant cell and regenerating a plant from said plant cell.

Another aspect of the invention provides the use of a nucleic acid, vector, cell or plant as described above in a method of producing a recombinant polypeptide as described herein.

5

Control experiments may be performed as appropriate in the methods described herein. The performance of suitable controls is well within the competence and ability of a skilled person in the field.

10

Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure. All documents mentioned in this specification are incorporated herein by

15 reference in their entirety.

Certain aspects and embodiments of the invention will now be illustrated by way of example and with reference to the figures described below.

20

Figure 1 shows the deduced amino acid sequence of CAH1. The arrow indicates the predicted signal peptide cleavage site. Underlined triplets indicate possible N-glycosylation sites.

25

Figure 2 shows the nucleotide sequence of Arabidopsis CAH1:

Figure 3 shows the structure of the GFP-tagged and truncated forms of the Arabidopsis CAH1 protein used to localize the domain required for plastid localization. (1-40)CAH1, GFP-fusion containing the signal peptide for the ER (first 40 aminoacids). (1-103)CAH1, GFP-fusion containing the first 103 aminoacids of the CAH1. (1-

40) CAH1-GFP-(224-284)CAH1, GFP-fusion containing the signal peptide for the ER (first 40 aminoacids) plus the last 61 aminoacid residues of the CAH1.

5 Experimental

Materials and Methods

Plant material and growth conditions

10 *Arabidopsis thaliana* plants, ecotype Columbia, were grown under a photon flux density of $150 \mu\text{mol m}^{-2} \text{s}^{-1}$ in a growth chamber. To obtain root material, surface-sterilized seeds (4 % sodium hypochlorite) were plated on 0.4 % agar plates supplemented with half strength Murashige and Skoog salts (Murashige, T. & Skoog, F. *Physiol. Plant.* 15, 15 473-497 (1962)). After three weeks, the seedlings were transferred to hydroponic conditions (Gibeaut, D.M. et al *Plant-Physiol.* 115, 317-319 (1997)). The roots were sampled after two weeks.

20 *Cloning*

A putative α -CA EST clone (*Arabidopsis thaliana*, GenBank accession number Z18493) was used to screen a total of 3.0×10^5 plaques from a Uni-ZAP™ XR *Arabidopsis thaliana* cDNA library (Stratagene). Nucleotide sequences of three 25 positive clones were determined and the 5'-end of the cDNA was identified through 5'-RACE-PCR experiments (Gibco-BRL). A genomic library was also screened and three positive clones were subcloned. A fragment covering the 5'-end of the gene and 728 bp upstream of the putative 30 translation initiation site was sequenced.

Southern and northern blot analysis.

Genomic DNA was extracted from developing *Arabidopsis* leaves, according to the method of Moore (Moore, D.D.

Preparation of genomic DNA from plant tissue. In Current protocols in molecular biology, F.M. Ausubel et al eds (John Wiley & Sons, Inc., USA) (1994)). Total RNA was isolated from developing *Arabidopsis* leaves and roots (Verwoerd, T.C. et al *Nucl. Acids Res.* 17, 2362 (1989)). Northern blot analysis was performed as previously described (Sambrook, J. et al *Molecular Cloning: A Laboratory Manual*, 2nd edn. (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press) (1989)).

Overexpression of recombinant CAH1 in *E. coli*.

PCR was used to amplify a selected cDNA region from CAH1 and cloned into *Bam*HI -*Xho*I digested expression vector pET23a(+) (Novagen). The resulting plasmid, pSLaCAH1, verified by direct sequencing, encodes a recombinant *Arabidopsis* CAH1 starting from Gly(28), with an N-terminal T7-tag and a C-terminal 6-histidine tag. The construct was transformed into *E. coli* BL21 (DE3) and the expressed recombinant protein was purified under denaturing conditions to near-homogeneity, using a histidine tag-binding resin, according to the pET System Manual (Novagen, Madison, WI, USA).

Antibody production

Polyclonal antibodies were raised against recombinant *Arabidopsis* CAH1 (Agri Sera AB, Sweden). The antibodies were purified using CAH1-coupled Affigel-10 (Bio-Rad), following the manufacturer's recommendations.

Protoplast and chloroplast isolation and fractionation.

Protoplasts were isolated from 5-10 g of *Arabidopsis* (5-7 week old) leaves, essentially according to Krömer et al (Krömer, S., et al *Plant Physiol.* 102, 947-955 (1993)), with the following slight modifications. Cell walls were digested with 1.3 % (w/v) cellulase and 0.4 % (w/v)

macerase (Calbiochem) for 2 hours at 28°C without extra illumination.

Protoplasts were disrupted and chloroplasts collected as described (Kunst, L. In *Methods in Molecular Biology* Volume 82. *Arabidopsis* protocols, J. Martinez-Zapater and J. Salinas, eds (Totowa, NJ: Humana Press Inc.), pp. 43-53 (1998)). The chloroplasts were further purified on a 50 % (v/v) Percoll gradient (Pharmacia Biotech). The supernatant, after the disruption and centrifugation of protoplasts, represents the cytosolic fraction. This fraction was further centrifuged at 20 800 g at 4°C for 30 min before samples were taken for western blot and marker-enzyme assays. The residual organelle and membrane pellet was resuspended in chloroplast resuspension buffer and stored for western blot analysis. Intact chloroplasts in chloroplast resuspension buffer were sonicated 3 x 30 s and centrifuged at 15,000 g for 30 min. The supernatant, mainly containing stroma proteins, was applied to a 1-mL MonoQ anion exchange column (HiTrap Q FF; Pharmacia, Sweden) equilibrated with 20 mM Tris-HCl buffer (pH 7.8). Bound proteins were eluted with a 30-mL linear gradient from 0 to 800 mM NaCl. Each fraction was desalted using PD-10 columns (Pharmacia). The purification process was monitored by subjecting aliquots from each fraction to western blot analyses.

Determination of chlorophyll and enzymatic markers.

Chlorophyll concentrations were determined in 80 % acetone according to the method of Porra et al (Porra, R.J et al *Biochim. Biophys. Acta.* 975, 384-394 (1989)). The activity of the chloroplast stromal marker NADP-glyceraldehyde-3-phosphate dehydrogenase (NADP-GAPDH) was determined as described (Winter, K et al *Plant Physiol.*

69, 300-307 (1982)), phosphoenol pyruvate carboxylase (PEPc) activity was measured, as a marker for the cytosol, as described (Gardeström, P. & Edwards, G.E. *Plant Physiol.* 71, 24-29 (1983)). The activity of the ER
 5 marker NADH-cytochrome *c* reductase was determined as described (Hodges, T.K. & Leonard, R.T. *Methods Enzymol.* 32, 397-398 (1974)).

Thermolysin treatments of intact chloroplasts were
 10 performed on ice for 30 min in 40 μ l reaction volumes (10 μ g chlorophyll in chloroplast resuspension buffer), using 200 μ g/ml thermolysin (Boehringer Mannheim).

2D-electrophoresis.

15 Stroma samples containing 300-400 μ g of protein were precipitated with 0.15 % (v/v) deoxycholic acid and 72 % (v/v) TCA as described³³ and solubilized in 2D rehydration solution, containing 8 M urea, 2 % (w/v) CHAPS, and 0.002 % (w/v) bromophenol blue. The solubilized samples were
 20 loaded onto linear immobilized pH gradient gels (IPG) covering the pH ranges from 4-7 and 3-10 (Amersham Pharmacia Biotech AB, Uppsala, Sweden). The samples were applied by in-gel-rehydration and isoelectrically focused using an IPGphor system (Amersham Pharmacia
 25 Biotech AB). After focusing, strips were equilibrated twice, for 15 min each time, in equilibration buffer (50 mM Tris-HCl (pH 8.8), 6 M urea, 30 % (v/v) glycerol, 0.002 % (v/v) bromophenol blue, and 2 % (w/v) SDS), containing 1 % (w/v) DTT in the first equilibration, and
 30 2.5 % (w/v) iodoacetamide in the second. After the equilibration steps, the strips were loaded onto 10 % SDS-PAGE gels, and electrophoretically separated at constant current. After 2D protein separation, stroma

proteins were detected using a silver-staining method as described (Blum, H. et al *Electrophoresis*. 8, 93-99 (1987)); or were electrotransferred onto nitrocellulose membrane.

5

Mass spectrometry and protein identification.

Proteins of interest were excised from the gels and, after in-gel digestion, analyzed by mass spectrometry using a Voyager Biospectrometry Workstation (PE Biosystems, CA, USA) matrix-assisted desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometer. The mass spectra obtained were internally calibrated using a mass standards kit (PerSeptive Biosystems, MA, USA) and used to search the NCBI database using the ProteinProspector program (available online from University of California, San Francisco). Database searches were performed using the following attributes with minor modifications, as required in each case: *Arabidopsis*, no restrictions for molecular weight and protein pI, trypsin digest, one missed cleavage allowed, cysteines modified by acrylamide, and oxidation of methionines possible, mass tolerance 50 ppm. Identification was considered positive when at least four peptides matched the protein or 30-40% coverage was obtained.

25

Western blot analysis.

Crude protein extracts were prepared from *Arabidopsis* leaf and root as described (Larsson, S., et al *Plant Mol. Biol.* 34, 583-592 (1997)). Protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad). SDS-PAGE was done following Laemmli (Laemmli, U. *Nature* 227, 680-685 (1970)).

30

Immunocytochemistry.

Developing *Arabidopsis* leaves were cut into 2 mm² pieces and fixed for 5 h at room temperature under a gentle vacuum. After several rinses, samples were dehydrated
 5 through a graded ethanol series and embedded in LR white resin (London Resin Co).

Immunolocalization at the light microscope level was carried out on 1-2 mm tissue sections, cut with a diamond
 10 knife on an LKB superfrost-plus microtome and then affixed to slides. The primary immune complexes were visualized by probing the sections for 2 h with colloidal gold-conjugates (6 nm) goat anti-rabbit IgG (diluted 1:100). The immuno-label was enhanced using a silver
 15 enhancement kit (Biocell), following the manufacturer's instructions, for 1 h until a black precipitate developed in the tissue. Sections were then counter-stained with toluidine blue and permanently mounted for observation on a Zeiss Axiophot microscope using bright field
 20 illumination.

Immunolocalization at the electron microscopy level was carried out on 150 nm ultra-thin sections picked up on uncoated 200-mesh nickel grids. The gold labelling was
 25 examined on an electron microscope after staining the grids in 2% aqueous uranyl acetate for 10 min.

Expression in reticulocyte lysate in the presence of dog pancreas microsomes.

30 The *CAH1* gene and the N-terminally truncated version (lacking positions 1-24) were cloned into pGEM1 (Promega) with the initiator ATG codon in the context of a "Kozak consensus" sequence (Kozak, M. *Annu. Rev. Cell Biol.* 8, 197-225 (1992)). The constructs were transcribed by SP6

RNA polymerase (Promega) for 1 hour at 37°C. The transcription mixture was as follows: 1-5 µg DNA template, 5 µl 10 x SP6 H-buffer (400 mM Hepes-KOH (pH 7.4), 60 mM Mg acetate, 20 mM spermidine-HCl), 5 µl BSA (1 mg/ml), 5 µl m7G(5')ppp(5')G (10mM) (Pharmacia), 5 µl DTT (50 mM), 5 µl rNTP mix (10 mM ATP, 10 mM CTP, 10 mM UTP, 5 mM GTP), 18.5 µl H₂O, 1.5 µl RNase inhibitor (50 units), 0.5 µl SP6 RNA polymerase (20 units). Translation was performed in reticulocyte lysate in the presence or absence of dog pancreas microsomes (Hermansson, M. et al *J. Mol. Biol.* 313, 1171-1179 (2001)). The acceptor peptide Benzoyl-NLT-methylamide (Quality Control Biochemicals inc.) was added as a competitive inhibitor of glycosylation with a final concentration of 200 µM. Translation products were analyzed by SDS-PAGE and gels were quantified on a Fuji FLA-3000 phosphoimager using Fuji Image Reader 8.1j software.

Construction of GFP reporter plasmids for transient expression in *Arabidopsis* and tobacco cells.

The GFP reporter plasmid 35Ω-sGFP(S65T) and the plasmid containing the transit peptide (TP) sequence from RBCS fused to GFP (35Ω-TP-sGFP(S65T)) have been previously described³⁹. The plasmids for expression of truncated *Arabidopsis* CAH1 protein fused to GFP were constructed as follows: The CaMV35S-CAH1-sGFP(S65T) corresponding to the coding region of *Arabidopsis* CAH1 was PCR-amplified using the two flanking primers for-*SalI* (TAAAAGTCGACATGAAGATTATGATGATGA) and rev1-*NcoI* (AAAACCCATGGAATTGGGTTTTTTCTTTTTT) and the PCR product was cloned into the *SalI*-*NcoI* digested GFP reporter plasmid CaMV35S-sGFP(S65T). The protocol was similar for the other constructions. The CaMV35S-(1-40)CAH1-sGFP(S65T) corresponding to CAH1 containing the first 40 amino acids

was PCR amplified using the two flanking primers for-*SalI* and rev2-*NcoI* (GTGTCCCATGGGGTTTGGTCCATTTTGGCC). The CaMV35S-(1-103)CAH1-sGFP(S65T) corresponding to CAH1 containing the first 103 amino acids was PCR amplified
 5 using the two flanking primers for-*SalI* and rev3-*NcoI* (TATCACCATGGCTGCTCCCTCCCCGAAGA). The CaMV35S-(1-40)CAH1-sGFP(S65T)-(224-284)CAH1 corresponding to CAH1 containing the first 40 and last 61 amino acids was PCR amplified using the two flanking primers for-*SalI* and rev2-*NcoI* and
 10 the two flanking primers for-*BsrGI* (TTCTTTGTACATCCTTGCGCAAGGTGAGGTC) and rev-*BsrGI* (GACAATGTACAACACTATTTTAATTGGGTTTTT). The plasmids were sequenced to check that the orientation and sequences of the inserted fragments were correct. The plasmids used
 15 for tissue bombardment were prepared using the QIAfilter plamid midi kit (Qiagen Laboratories).

Bombardment and fluorescence microscopy of Arabidopsis and tobacco cells.

20 Plasmids of appropriate constructions (5 µg) were introduced into *Arabidopsis* and tobacco BY2 cells using a pneumatic particle gun (PDS-1000/He; Bio-Rad). The conditions of bombardment have been previously reported (Miras, S. et al. *J. Biol. Chem.* 277, 47770-47778
 25 (2002)). After bombardment, cells were incubated on the plates for 18-36 h (in light for the *Arabidopsis* cells, in the dark for BY2 cells). Cells were transferred to glass slides before fluorescence microscopy.

30 Localization of GFP and GFP fusions was analyzed in transformed cells by fluorescence microscopy using a Zeiss Axioplan2 fluorescence microscope, and the images were captured with a digital charge-coupled devices

camera, using filter sets described by Miras et al (supra).

Results

An *Arabidopsis* EST (Z18493) was identified which

5 potentially codes for an α -carbonic anhydrase (α -CA).

Sequencing of the clone showed that it contained a 1046 bp open reading frame encoding a polypeptide of 284 amino acids (Figure 1). The cDNA clone was used to isolate a

10 corresponding genomic clone, and the 5'-end of the gene and 728 bp upstream from the putative translation initiation site were sequenced. The sequence was in complete accordance with the open reading frame and upstream region of a single gene on chromosome 3 (At3g52720), which we denoted *CAH1* (U73462).

15

RNA was prepared from *Arabidopsis* leaf and root material and subjected to RNA blot analysis. A single hybridizing band of approximately 1200 bases was identified in leaf RNA using a fragment of the *CAH1* cDNA as a probe. No such

20 signal was detected in root RNA. The *CAH1* gene was observed to have a very pronounced diurnal variation in expression level, peaking within the first hours of the light period.

25 Specific antibodies raised against *Arabidopsis* *CAH1* recognized a polypeptide with an apparent molecular mass of ~ 38 kDa in leaf, but not root, protein samples, confirming the northern blot data. Thus, *CAH1* was observed to be expressed mainly in photosynthetic

30 tissues.

Immunolocalization analysis was performed in *Arabidopsis* leaves to localize *CAH1* within the plant cell.

Unexpectedly, the results indicated that CAH1, despite its predicted sorting to the secretory pathway, was located exclusively in the chloroplast stroma.

- 5 Leaf protoplasts were fractionated into chloroplasts, cytosol and a residual organelle and membrane pellet, then assayed the CAH1 localization. Marker-enzymes for the chloroplast stroma (NADP-GAPDH) and the cytosol (PEPc) were used to assess the purity of the fractions.
- 10 The activity of each enzyme in intact protoplasts was set to 100 %. A small degree of contamination (4.5 %) of chloroplast enzymes was observed in the cytosolic fraction. The degree of contamination of the chloroplast fraction by cytosolic material was 24%, most probably due
- 15 to the aggregation of chloroplasts (observed under the microscope), resulting in cytosolic enzymes being trapped. Around 60 % of the chloroplasts were intact. The broken chloroplasts explain the relatively low activity of the chloroplast marker enzyme (65 % instead of 100 %)
- 20 in the chloroplast fraction. Because of the presence of a signal peptide for the ER in the unprocessed CAH1 protein, the degree of contamination of the chloroplast fraction by ER vesicles was also checked. Activity of the ER marker enzyme NADH-cytochrome c reductase was barely
- 25 detectable in the chloroplast fraction. Nevertheless, western blot analysis, using CAH1-specific antibodies, showed that this CA is specifically located in the chloroplast fraction. A faint band was also observed in the cytosolic fraction, probably due to contamination
- 30 from the broken chloroplasts. No CAH1 was found in the residual organelle and membrane pellet. The CAH1 protein in chloroplasts did not appear to be associated with the outer envelope surface, nor to protrude into the cytosol, since the protein was completely resistant to thermolysin

treatment of intact chloroplasts, but susceptible after lysis of the chloroplasts. This is in accordance with the stromal localization of CAH1 observed by immunoelectron microscopy.

5

A translational fusion of green fluorescent protein (GFP) with the C-terminus of *Arabidopsis* CAH1 was transiently expressed in *Arabidopsis* and tobacco cells. The CAH1-GFP fusion protein was targeted to the chloroplasts in both
10 *Arabidopsis* and tobacco cells. The expressed GFP protein (negative control) was distributed uniformly in the cytosol and in the nucleus, whereas the chloroplast control (the transit sequence of RbcS fused to GFP) was targeted to the chloroplast. Sequence information in CAH1
15 was therefore sufficient for chloroplast targeting of the fusion protein *in vivo*. Taken together, these findings clearly demonstrate that CAH1 is located in the chloroplast stroma of *Arabidopsis*, despite the presence of a typical ER-targeting signal peptide.

20

In vitro uptake studies were performed both with isolated chloroplasts, and with ER-derived dog pancreas microsomes (Monné, M. et al *J. Biol. Mol.* 293, 807 (1999)). Intact pea chloroplasts were not able to take up or process the
25 CAH1 precursor, providing indication that the translocation of CAH1 across the envelope membranes may not take place through the Tic/Toc translocon system. Efficient uptake, signal peptide processing, and glycosylation were observed with microsomes.

30

The CAH1 protein has five predicted acceptor sites for N-linked glycosylation (Fig. 1), and major products with relative molecular masses of approximately 38, 41 and 44 kDa were observed in addition to the non-modified 31-kDa

protein, providing indication that at least four glycosylation sites may be partially modified. Although removal of the signal peptide leads only to a small shift in mobility, a product corresponding to the protein lacking the signal peptide is clearly seen when glycosylation is blocked. These findings provide indication that CAH1 is taken up by the ER and glycosylated before being targeted into the chloroplast.

For further examination of the domain required for chloroplast localization of the CAH1 protein, several versions of the CAH1 protein were generated and the effects of transiently expressing corresponding GFP fusions in *Arabidopsis* and BY2 tobacco cells were tested (Figure 3). No GFP activity was observed in the chloroplasts for any of the constructs used.

Despite its chloroplast localization, CAH1 has an N-terminal signal peptide that targets the protein to the ER. Stroma were isolated from *Arabidopsis* chloroplasts and fractionated it by anion exchange chromatography. The CAH1-containing fraction was separated by 2D-gel electrophoresis, and either silver stained or blotted onto nitrocellulose membranes. The membranes were then incubated with antibodies raised against CAH1, $\beta(1,2)$ -xylose, and $\alpha(1,3)$ -fucose epitopes. These two antibodies recognize xylose- and fucose-containing glycans N-linked to Asn-x-Thr/Ser sites, respectively (Faye, L. et al. *Anal. Biochem.* 209, 104-108 (1993)): linkages that are typical of plants and are specifically transferred to N-glycans within the Golgi apparatus (Lerouge, P., et al. *Plant Mol. Biol.* 38, 31-48 (1998)). Antibodies raised against CAH1 cross-reacted with a protein at ~38 kDa with a variable pI value ranging from 5.2 to 5.6 (Fig. 5b).

Antibodies raised against $\beta(1,2)$ -xylose and $\alpha(1,3)$ -fucose cross-reacted with the same protein recognized by the CAH1 antibodies, providing indication that the mature stromal CAH1 protein is N-glycosylated.

5

CAH1 was not the only glycosylated protein found to be present in the stroma of *Arabidopsis*. By comparing 2D-gels (covering the pH ranges from 4-7 and 3-10) from different stroma preparations, we have identified approximately 6-10 different spots that cross-react with both xylose and fucose antibodies.

10

Therefore, some of these protein spots were excised and subjected to MALDI-TOF MS analysis, which positively identified a putative chloroplast 50S ribosomal protein (At1g05190.1; spot no. 1) and an unknown protein (At4g04240.1; spot no. 2). NetNGlyc analysis for predicting potential N-glycosylation sites (Gupta R & Brunak S (2002) Pac. Symp. Biocomput. 310-322) strongly predicts that 1-3 acceptor sites for N-linked glycosylation are contained in the sequence of these two proteins. These data show that N-glycosylation of stromal proteins in *Arabidopsis thaliana* is not restricted to CAH1.

25

The C-termini of both CAH1 and the putative chloroplast 50S ribosomal protein show high degrees of similarity. They are extremely hydrophilic (16 of 19 residues, and nine of the last 15 C-terminal amino acid residues, are charged, including six and five lysine residues, respectively). This C-terminus may be important for the mechanism whereby these proteins are imported to the chloroplast.

30

The data herein provides firm evidence that the chloroplast proteome contains glycosylated proteins which are sorted through the ER, in addition to those proteins which are synthesized in the chloroplast and those which are transported through the Tic/Toc translocon complex.

Since different types of plastid are of similar origin and can re-develop into each other, these findings have significant application in the expression of recombinant plastid polypeptides.

Gene ID	Description	NA Acc No:	AA Acc no
AT1G03860	prohibitin 2 -related B-cell receptor associated protein	NM_202027	NP_973756
AT1G09180	GTP-binding protein SAR1, putative strong similarity to SP:Q01474 GTP-binding protein SAR1B and SP:O04834 GTP-binding protein SAR1A [Arabidopsis thaliana]	NM_100788	NP_172390
AT1G13900	calcineurin-like phosphoesterase family contains Pfam profile: PF00149 calcineurin-like phosphoesterase	NM_101256	NP_172843
AT1G15690	inorganic pyrophosphatase -related similar to inorganic pyrophosphatase GI:790478 from [Nicotiana tabacum]	NM_101437	NP_173021
AT1G26560	glycosyl hydrolase family 1 similar to beta-glucosidase GB:L41869 GI:804655 from [Hordeum vulgare]	NM_102418	NP_173978
AT1G29670	"GDSL-motif lipase/hydrolase protein similar to family II lipase EXL1 GI:15054382 from [Arabidopsis thaliana]; contains Pfam profile: PF00657 Lipase/Acylhydrolase with GDSL-like motif"	NM_102707	NP_174260
AT1G30360	ERD4 protein nearly identical to ERD4 protein (early-responsive to dehydration stress) [Arabidopsis thaliana] GI:15375406; contains Pfam profile PF02714: Domain of unknown function DUF221	NM_102773	NP_564354
AT1G33590	"disease resistance protein-related (LRR) contains leucine rich-repeat domains Pfam:PF00560, INTERPRO:IPR001611; similar to Hcr2-5D [Lycopersicon esculentum] gi 3894393 gb AAC78596"	NM_103082	NP_564426
AT1G47128	cysteine proteinase RD21A identical to thiol protease RD21A SP:P43297 from [Arabidopsis thaliana]	NM_103612	NP_564497
AT1G49750	leucine rich repeat protein family contains leucine-rich repeats, Pfam:PF00560	NM_103862	NP_175397
AT1G61790	Hypothetical protein	NM_104861	NP_176372
AT1G66770	"nodulin MtN3 family protein contains Pfam PF03083 MtN3/saliva family; similar to LIM7 (cDNAs induced in meiotic prophase in lily microsporocytes) GI:431154 from [Lilium longiflorum]"	NM_105348	NP_176849
AT1G68560	glycosyl hydrolase family 31 (alpha-xylosidase) identical to alpha-xylosidase precursor GB:AAD05539 GI:4163997 from [Arabidopsis thaliana]	NM_105527	NP_177023
AT1G74180	"leucine rich repeat protein family contains leucine rich-repeat (LRR) domains Pfam:PF00560, INTERPRO:IPR001611; similar to Hcr2-0B	NM_106078	NP_177558

	[Lycopersicon esculentum] gi 3894387 gb AAC78593"		
AT2G06850	xyloglucan endotransglycosylase (ext/EXGT-A1) identical to endo-xyloglucan transferase (ext) GI:469484 and endoxyloglucan transferase (EXGT-A1) GI:5533309 from [Arabidopsis thaliana].	NM_126666	NP_178708
AT2G10940	"protease inhibitor/seed storage/lipid transfer protein (LTP) family similar to proline-rich cell wall protein [Medicago sativa] GI:3818416; contains Pfam profile PF00234 Protease inhibitor/seed storage/LTP family"	NM_179618	NP_849949
AT2G22170	expressed protein	NM_127785	NP_565527
AT2G37290	Hypothetical protein and genefinder	NM_129285	NP_181266
AT2G45740	expressed protein	NM_180110	NP_850441
AT3G05660	"disease resistance protein family contains leucine rich-repeat (LRR) domains Pfam:PF00560, INTERPRO:IPR001611; similar to Cf-2.2 [Lycopersicon pimpinellifolium] gi 1184077 gb AAC15780"	NM_111439	NP_187217
AT3G14210	"myrosinase-associated protein, putative similar to GB:CAA71238 from [Brassica napus]; contains Pfam profile:PF00657 Lipase/Acylhydrolase with GDSL-like motif"	NM_112278	NP_188037
AT3G14590	"C2 domain-containing protein low similarity to SP Q16974 Calcium-dependent protein kinase C (EC 2.7.1.-) [Aplysia californica]; contains Pfam profile PF00168: C2 domain"	NM_112319	NP_188077
AT3G16240	delta tonoplast integral protein (delta-TIP) identical to delta tonoplast integral protein (delta-TIP) GB:U39485 [Arabidopsis thaliana] (Plant Cell 8 (4), 587-599 (1996))	NM_112495	NP_188245
AT3G20820	"disease resistance protein family (LRR) contains similarity to Cf-2.1 [Lycopersicon pimpinellifolium] gi 1184075 gb AAC15779; contains leucine rich-repeat domains Pfam:PF00560, INTERPRO:IPR001611"	NM_112973	NP_188718
AT3G27280	prohibitin -related similar to prohibitin GB:AAC49691 from [Arabidopsis thaliana] (Plant Mol. Biol. (1997) 33 (4), 753-756)	NM_202640	NP_974369
AT3G54110	uncoupling protein (ucp/PUMP)	NM_115271	NP_190979
AT3G54400	nucleoid DNA-binding - like protein nucleoid DNA-binding protein cnd41, chloroplast, common tobacco, PIR:T01996	NM_115300	NP_191008
AT3G55200	"splicing factor, putative contains CPSF A subunit region (PF03178); contains weak WD-40 repeat (PF00400); similar to Splicing factor 3B subunit 3 (SF3b130)/spliceosomal protein/Splicing factor 3B subunit 3 (SAP 130) (KIAA0017) (SF:Q15393) Homo sapiens, EMB	NM_115378	NP_567015
AT4G17340	major intrinsic protein (MIP) family contains Pfam profile: MIP PF00230	NM_117838	NP_193465

AT4G27520	expressed protein ENOD20 gene, Medicago truncatula, X99467	NM_118887	NP_194482
AT4G39730	expressed protein	NM_120134	NP_195683
AT5G02260	"expansin, putative (EXP9) similar to expansin precursor GI:4138914 from [Lycopersicon esculentum]; alpha-expansin gene family, PMID:11641069"	NM_120304	NP_195846
AT5G03350	expressed protein	NM_120414	NP_195955
AT5G07340	"calnexin, putative identical to calnexin homolog 2 from Arabidopsis thaliana [SP Q38798], strong similarity to calnexin homolog 1, Arabidopsis thaliana, EMBL:AT08315 [SP P29402]; contains Pfam profile PF00262 calreticulin family"	NM_120816	NP_196351
AT5G12860	Oxoglutarate/malate translocator, putative similar to 2-oxoglutarate/malate translocator precursor, spinach, SWISSPROT:Q41364	NM_121289	NP_568283
AT5G25980	glycosyl hydrolase family 1 similar to myrosinase precursor (EC 3.2.3.1) (Sinigrinase) (Thioglucosidase) SP P37702 from [Arabidopsis thaliana]	NM_122499	NP_568479
AT5G26000	glycosyl hydrolase family 1, myrosinase precursor	NM_122501	NP_197972
AT5G26260	expressed protein various predicted proteins, Arabidopsis thaliana	NM_122527	NP_568483
AT5G44020	vegetative storage protein-related	NM_123769	NP_199215
AT5G63840	glycosyl hydrolase family 31 similar to alpha-glucosidase GI:2648032 from [Solanum tuberosum]	NM_125779	NP_201189
AT5G65760	"hydrolase, alpha/beta fold family similar to SP P42785 Lysosomal Pro-X carboxypeptidase precursor (EC 3.4.16.2) (Prolylcarboxypeptidase) (PRCP) (Proline carboxypeptidase) (Homo sapiens); contains Pfam profile PF00561: hydrolase, alpha/beta fold family"	NM_125973	NP_201377
At2g31910	putative Na ⁺ /H ⁺ antiporter	NM_128749	NP_180750
At2g01720	Ribophorin I-like protein	NM_126233	NP_178281
At4g20990	Carbonic anhydrase	NM_118217	NP_193831
At4g39730	Expressed protein	NM_120134	NP_195683
At1g21750	Protein disulfide isomerase	NM_179365	NP_849696

Table 1

Claims:

1. A method of producing a recombinant polypeptide, comprising;
5 expressing a glycosylated recombinant polypeptide in the plastid of a plant cell.
2. A method of producing a recombinant polypeptide comprising;
10 expressing in a plant cell a nucleic acid encoding a fusion polypeptide which comprises said recombinant polypeptide, an ER signal sequence and one or more ER-plastid targeting sequences.
- 15 3. A method according to claim 2 wherein said plant ER signal sequence is from an ER processed plastid polypeptide.
4. A method according to claim 2 or claim 3 wherein the
20 one or more ER-plastid targeting sequences comprise at least 10 contiguous amino acids from an ER-processed plastid polypeptide.
5. A method according to claim 4 wherein the at least
25 10 contiguous amino acids comprise two or more contiguous basic residues.
6. A method according to any one of claims 2 to 5 wherein the one or more ER-plastid targeting sequences
30 are comprised within an ER-processed plastid polypeptide.

7. A method according to claim 6 wherein the ER-processed plastid polypeptide has a sequence shown in Table 1.

5 8. A method according to claim 6 wherein the ER-processed plastid-localised polypeptide is a CAH1 polypeptide.

9. A method according to any one of claims 2 to 8
10 comprising cleaving said expressed fusion polypeptide to generate said recombinant polypeptide.

10. A method according to claim 9 wherein the expressed fusion polypeptide comprises one or more cleavable linker
15 sequences, said recombinant polypeptide being generated by cleavage of said one or more linker sequences.

11. A method according to claim 10 wherein said one or more linker sequences are cleaved within said plastid by
20 a heterologous endoprotease to generate said recombinant polypeptide.

12. A method according to claim 10 wherein said one or more linker sequences are cleaved within said plastid by
25 an endogenous plastid endoprotease to generate said recombinant polypeptide.

13. A method according to any one of the preceding claims comprising isolating and/or purifying said
30 recombinant polypeptide from a plastid of said cell.

14. A method according to any one of claims 1 to 10 comprising isolating and/or purifying said expressed

fusion polypeptide from a plastid of said cell prior to cleavage to generate said recombinant polypeptide.

15. A method according to any one of the preceding
5 claims wherein the recombinant polypeptide comprises one or more glycosylation sites.

16. A method according to claim 15 comprising
determining the glycosylation of the expressed
10 recombinant polypeptide.

17. A method according to any one of the preceding
claims wherein said plastid is a chloroplast.

15 18. A nucleic acid construct comprising;
a nucleotide sequence which encodes an ER signal
sequence,
one or more ER-plastid targeting sequences, and;
one or more restriction endonuclease sites for
20 insertion of a nucleotide coding sequence capable of
expressing a recombinant polypeptide fused to said ER
signal and ER-plastid targeting sequences.

19. A nucleic acid construct according to claim 18
25 comprising;
a nucleotide coding sequence capable of expressing a
recombinant polypeptide fused to said ER signal and ER-
plastid targeting sequences,
said coding sequence being inserted in the one or
30 more restriction endonuclease sites.

20. A nucleic acid construct according to claim 18 or
claim 19 wherein the nucleotide sequence further encodes
one or more cleavable linker sequences,

said recombinant polypeptide being generated by cleavage of said one or more linker sequences.

21. A nucleic acid construct according to any one of
5 claims 18 to 20 wherein said ER signal sequence is from an ER-processed plastid polypeptide.

22. A nucleic acid construct according to any one of
10 claims 18 to 21 wherein the one or more ER-plastid targeting sequences comprise at least 10 contiguous amino acids from an ER-processed plastid polypeptide.

23. A nucleic acid construct according to any one of
15 claims 18 to 22 wherein the one or more ER-plastid targeting sequences comprise two or more contiguous basic residues.

24. A nucleic acid construct according to any one of
20 claims 18 to 23 wherein the ER signal sequence and one or more ER-plastid targeting sequences are comprised within an ER-processed plastid polypeptide sequence.

25. A nucleic acid construct according to any one of
25 claims 18 to 24 wherein the ER-processed plastid localised polypeptide sequence is a sequence shown in Table 1.

26. A nucleic acid construct according to any one of
30 claims 18 to 24 wherein the ER-processed plastid-localised polypeptide sequence is a CAH1 polypeptide.

27. A nucleic acid construct according to any one of
claims 18 to 26 wherein said plastid is a chloroplast.

28. A nucleic acid vector suitable for transformation of a plant cell and comprising a nucleic acid construct according to any one of claims 18 to 27.

5 29. A host cell comprising a nucleic acid construct according to any one of claims 18 to 27 or a vector according to claim 28.

10 30. A host cell according to claim 29 having said nucleic acid construct or vector within its genome.

31. A host cell according to claim 29 or claim 30 which is a plant cell.

15 32. A plant cell according to claim 31 which comprises nucleic acid encoding one or more mammalian glycosyltransferases.

20 33. A plant cell according to claim 31 or claim 32 which is deficient in one or more plant specific glycosyltransferases.

25 34. A plant cell according to any one of claims 31 to 33 which is comprised in a plant, a plant part or a plant propagule, or extract or derivative of a plant.

30 35. A method of producing a cell according to any one of claims 29 to 33 the method comprising incorporating said nucleic acid construct or vector into the cell by means of transformation.

36. A method according to claim 35 which comprises combining the nucleic acid with the cell genome nucleic acid such that it is stably incorporated therein.

37. A method according to claim 35 or claim 36 which comprises regenerating a plant from one or more transformed cells.

5

38. A method according to claim 37 comprising sexually or asexually propagating or growing off-spring or a descendant of the plant regenerated from said plant cell.

10 39. A plant comprising a cell according to any one of claims 31 to 33.

40. A method of producing a plant according to claim 36, the method comprising incorporating a nucleic acid
15 construct according to any one of claims 18 to 27 into a plant cell and regenerating a plant from said plant cell.

41. Use of a nucleic acid according to any one of claims 18 to 27, a vector according to claim 28, a cell
20 according to any one of claims 29 to 33 or a plant according to claim 39 in a method of producing a recombinant polypeptide.

25

10 20 30 40 50
 MKIMMMIKLCFFSMSLICIA[↓]PADAQTEGVVFGYKGKNGPNQWGH[↓]LNPHFT
 TCAVGKLQSPIDIQRRQIFYNHKLNSIHREYYFTNATLVNHVCNVAMFFG
 EGAGDVIIENKNY[↓]TLLQMHWHTPSEHHLHGVQYAAELHMHVQA[↓]KDGSFAV
 VASLFKIGTEEPFLSOMKEKLVKLKEERLKGNHTAQVEVGRIDTRHIERK
 TRKYRYIGSLTTPPCSENV[↓]SWTILGKVRSMSKEQVELLRSP[↓]LDTSFKNN
 SRPCQPLNGRRVEMFHDHERVDKKETGNKKKKPN

Figure 1

1 atgcagtaat ctgataaaac cctccacaga gatttccaac aaaacaggaa ctaaaacaca
 61 agatgaagat tatgatgatg attaagctct gcttcttctc catgtccctc atctgcattg
 121 cacctgcaga tgctcagaca gaaggagtag tgtttggata taaaggcaaa aatggaccaa
 181 accaatgggg acacttaaac cctcacttca ccacatgcgc ggtcggtaaa ttgcaatctc
 5 241 caattgatat tcaaaggagg caaatatttt acaaccacaa attgaattca atacaccgtg
 301 aatactactt cacaaacgca acactagtga accacgtctg taatggtgcc atgttcttcg
 361 gggaggggagc aggagatgtg ataatagaaa acaagaacta taccttactg caaatgcatt
 421 ggcacactcc ttctgaacat cacctccatg gagtccaata tgcagctgag ctgcacatgg
 481 tacaccaagc aaaagatgga agctttgctg tgggtggcaag tctcttcaaa atcggcactg
 10 541 aagagccttt cctctctcag atgaaggaga aattggtgaa gctaaaggaa gagagactca
 601 aagggaaacca cacagcacia gtggaagtag gaagaatcga cacaagacac attgaacgta
 661 agactcgaaa gtactacaga tacattggtt cactcactac tcctccttgc tccgagaacg
 721 tttcttggac catccttggc aaggtgaggt caatgtcaaa ggaacaagta gaactactca
 781 gatctccatt ggacacttct ttcaagaaca attcaagacc gtgtcaaccc ctcaacggcc
 15 841 ggagagttga gatgttccac gaccacgagc gtgtcgataa aaaagaaacc ggtaacaaaa
 901 agaaaaaacc caattaaaat agttttacat tgtctattgg tttgtttaga accctaatta
 961 gctttgtaaa actaataatc tcttatgtag tactgtgttg ttgtttacga cttgatatac
 1021 gatttccaaa aaaaaaaaaa aaaaaa




Figure 3

10 20 30 40 50
MKIMMMIKLCFFSMSLICIA[↓]PADAQTEGVVFGYKGKNGPNQWGHLNPHFT
TCAVGKLOSPIDIQRRQIFYNHKLNSIHREYYFTNATLVNHVCNVAMFFG
EGAGDVIIENKNYTLLOMHWHTPSEHHLHGVQYAAELHMHVQAKDGSFAV
VASLFKIGTEEPFLSOMKEKLVKLKEERLKGNHTAQVEVGRIDTRHIERK
TRKYYRYIGSLTTPPCSENSWTILGKVRSMSKEQVELLRSPLDTSFKNN
SRPCQPLNGRRVEMFHDHERVDKKETGNKKKKPN

Figure 1

1 atgcagtaat ctgataaaac cctccacaga gatttccaac aaaacaggaa ctaaaacaca
 61 agatgaagat tatgatgatg attaagctct gcttcttctc catgtccctc atctgcattg
 121 cacctgcaga tgctcagaca gaaggagtag tgtttgata taaaggcaaa aatggaccaa
 181 accaatgggg acacttaaac cctcacttca ccacatgcgc ggtcggtaaa ttgcaatctc
 5 241 caattgatat tcaaaggagg caaatatddd acaaccacaa attgaattca atacaccgtg
 301 aatactactt cacaaacgca acactagtga accacgtctg taatggtgcc atgttcttcg
 361 gggaggggagc aggagatgtg ataataaaaa acaagaacta taccttactg caaatgcatt
 421 ggcacactcc ttctgaacat cacctccatg gagtccaata tgcagctgag ctgcacatgg
 481 tacaccaagc aaaagatgga agctttgctg tgggtggcaag tctcttcaaa atcggcactg
 10 541 aagagccttt cctctctcag atgaaggaga aattggtgaa gctaaaggaa gagagactca
 601 aaggggaacca cacagcacia gtggaagtag gaagaatcga cacaagacac attgaacgta
 661 agactcgaaa gtactacaga tacattgggt cactcactac tctccttgc tccgagaacg
 721 tttcttggaac catccttggc aaggtgaggt caatgtcaaa ggaacaagta gaactactca
 781 gatctccatt ggacacttct ttcaagaaca attcaagacc gtgtcaaccc ctcaacggcc
 15 841 ggagagttga gatgttcac gaccacgagc gtgtcgataa aaaagaaacc ggtaacaaaa
 901 agaaaaaacc caattaaaat agttttacat tgtctattgg tttgtttaga accctaatta
 961 gctttgtaaa actaataatc tcttatgtag tactgtgttg ttgtttacga cttgatatac
 1021 gatttccaaa aaaaaaaaaa aaaaaa

20

Figure 2




Figure 3

PCT/IB2004/003726



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.